Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysisScott Goldsmith, Marcie Riches, Miguel Ángel Díaz et al.|Blood|2021Cited by 177
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistryMaría Silvina Odstrcil Bobillo, Matthew J. Frigault, Swetha Kambhampati et al.|Blood|2024Cited by 7
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistrySairah Ahmed, Jennifer L. Crombie, Avyakta Kallam et al.|Blood|2024Cited by 6
Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) and Secondary CNS (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistrySairah Ahmed, Jennifer L. Crombie, Avyakta Kallam et al.|Transplantation and Cellular Therapy|2025Cited by 2
Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell Lymphoma (tLBCL): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) RegistryIris Isufi, Sairah Ahmed, Matthew J. Frigault et al.|Transplantation and Cellular Therapy|2025Cited by 1